Trial Profile
Open-label Single Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of nemolizumab in Pediatric Patients with Atopic Dermatitis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Nemolizumab (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Maruho
- 11 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2017 New trial record